US Equities
What Caused The AIM ImmunoTech Stock To Rise In Pre-Hours Session?
Following good clinical trial findings, AIM ImmunoTech Inc. (NYSE: AIM) is soaring today, up 3.66% to trade at $0.38 at the last check in premarket activity. What outcomes has AIM disclosed? Lisanne C.A. Smidt of the Centre for Human Drug Research (CHDR), Leiden, the Netherlands,
